Literature DB >> 8405316

Hepatitis B mass immunization of adolescents: a pilot study in a community.

S Plaitano1, L Sagliocca, A Mele, C Bove, D Protano, B Adamo, F Palumbo, M Cauletti, E Franco, P Pasquini.   

Abstract

The National Type Specific Hepatitis Surveillance System (SEIEVA) and seroepidemiological studies have shown that in addition to newborns from mothers who are carriers for hepatitis B surface antigen (HBsAg), adolescents are at high risk of acquiring type B hepatitis virus because of increasing importance of the heterosexual transmission of this virus. In order to evaluate logistic problems and acceptance rate of adolescents to mass vaccination against hepatitis B, a pilot study was carried out among all 7th grade children registered in the 9 schools of an hepatitis B endemic area located in the suburbs of Naples. After meetings held by the local health department with school teachers and parents, 1219 out of 1250 (97.5%) invited children received the first dose of hepatitis B vaccine; 1215 and 1209 received, respectively, the second and third doses. Anti-hepatitis B surface antigen (anti-HBs) values were studied in 406 subjects one month after the third dose, and 21 out of 406 (5.2%) had anti-HBs values less than 10 IU/L. We consider 95% of subjects with anti-HBs values greater than 9 IU/L a good achievement for a field vaccination program. The high acceptance rate of vaccination found in our study outlines the importance of active offer of vaccination combined with school involvement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405316     DOI: 10.1007/bf00146268

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  7 in total

1.  Changing epidemiology of hepatitis B in Italy: public health implications.

Authors:  R D'Amelio; P M Matricardi; R Biselli; T Stroffolini; A Mele; E Spada; P Chionne; M Rapicetta; L Ferrigno; P Pasquini
Journal:  Am J Epidemiol       Date:  1992-05-01       Impact factor: 4.897

2.  Epidemiology of hepatitis B in Italy.

Authors:  L Dardanoni; A Mele; M C Polizzi
Journal:  Ann Ist Super Sanita       Date:  1987       Impact factor: 1.663

3.  Prevalence of hepatitis B markers in Italy.

Authors:  P Pasquini; H A Kahn; D Pileggi; A Panà; J Terzi; E Guzzanti
Journal:  Am J Epidemiol       Date:  1983-11       Impact factor: 4.897

4.  Decline of incidence of A, B and non-A, non-B hepatitis in Italy. Results of four years surveillance (1985-88). SEIEVA collaborating group.

Authors:  A Mele; M A Stazi; R Corona; L Ferrigno; L Sagliocca; F Palumbo; P Falasca; C Galanti; A Moiraghi; F Rosmini
Journal:  Ital J Gastroenterol       Date:  1990-10

5.  Hepatitis B virus infection in children in Sardinia, Italy.

Authors:  T Stroffolini; E Franco; G Romano; P Uccheddu; P Pasquini; A Panà; A Maida; B Scarpa
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

6.  Age-specific prevalence of hepatitis B virus infection among children in an endemic area in southern Italy.

Authors:  T Stroffolini; D De Mattia; A Compagnone; G P Arcamone; M Altomare; F Schettini
Journal:  Pediatr Infect Dis J       Date:  1990-06       Impact factor: 2.129

7.  Decline in the exposure to hepatitis A and B infections in children in Naples, Italy.

Authors:  P D'Argenio; D Esposito; A Mele; G Ortolani; B Adamo; M Rapicetta; P Forte; A Pisani; L Soldo; B Sarrecchia
Journal:  Public Health       Date:  1989-09       Impact factor: 2.427

  7 in total
  2 in total

1.  Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren.

Authors:  Maryse Guay; Anne-Marie Clouâtre; Manon Blackburn; Geneviève Baron; Philippe De Wals; Chantale Roy; Jean Desrochers; François Milord
Journal:  Can J Public Health       Date:  2003 Jan-Feb

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.